Details of the Drug Reposition

General Information of This Drug (ID: DMQUSBT)

• Drug Name: Daunorubicin (DMQUSBT)
• Synonyms: daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

5 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Leukemia	DISNAKFL	N.A.	Approved	[1]
Acute monocytic leukemia	DIS28NEL	N.A.	Approved	[1]
Acute myelogenous leukaemia	DISCSPTN	2A41	Approved	[1]
Acute myeloid leukaemia	DIS0BM1I	2A60	Approved	[2]
Kaposi sarcoma	DISC1H1Z	2B57	Approved	[3]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[4]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute erythroid leukemia	DISZFC1O	N.A.	Withdrawn	[5]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Promyelocytic leukaemia	DISYGG13	2A82.1	Discontinued in Phase 2	[6]

1 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute lymphocytic leukaemia	DISPX75S	2B33.3	Discontinued in Phase 1	[7]

References

• [1] Daunorubicin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
• [5] Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
• [6] Study of Sutent/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
• [7] ClinicalTrials.gov (NCT01347866) Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer